Cisplatin News and Research

RSS

Adding berzosertib to standard treatment for metastatic urothelial cancer does not extend patient survival

A Phase 2 trial led by City of Hope, a world-renowned research and treatment center for cancer and diabetes, suggests that adding the novel ataxia telangiectasia and Rad3-related (ATR) inhibitor drug berzosertib to standard-of-care chemotherapy for patients with metastatic urothelial cancer does not extend progression-free survival.

27 Aug 2021

Removal of race from kidney function estimates may negatively impact care for Black cancer patients

An accurate assessment of a patient's kidney function is critical for determining eligibility for anticancer treatments.

14 Aug 2021

New research offers hope to increase efficacy of immunotherapy for lung cancer

Lung cancer is the leading cause of cancer-related death. Current treatments employ immunotherapy, often in combination with chemotherapy, but benefits to patients remain slight.

11 Aug 2021

Research shines new light on deadly medulloblastoma metastases

With advances in medical science driving progress against childhood brain tumors, today three out of four young patients survive at least five years beyond diagnosis. However, the outcomes look grim when malignant cells spread, or metastasize.

29 Jun 2021

Repressing a protein that facilitates DNA repair to potentiate chemotherapy

Chemotherapy kills tumor cells by causing damage to them. One of the most effective ways of causing damage is to prevent the two DNA strands from separating so that the cellular machinery cannot read the instructions written in the genes.

15 Jun 2021

Superoxide produced in the inner ear cochlea causes major types of acquired hearing loss

Professor UEYAMA Takehiko (Biosignal Research Center, Kobe University) and the inner ear research group (Kyoto Prefectural University of Medicine) have identified the cell types in the inner ear cochlea responsible for the production of superoxide (Nox3-expressing cells).

25 May 2021

Targeting mTOR pathway can improve the effectiveness of chemotherapies for pediatric brain cancer

Two experimental drug approaches that target vulnerabilities in cancer cell metabolism may extend survival and enhance the effectiveness of standard chemotherapies for a highly aggressive type of pediatric brain cancer.

21 May 2021

Scientists identify receptor in cells that could be key to preventing cancer drug-induced hearing loss

University of Alberta scientists have identified a receptor in cells that could be key to preventing permanent hearing loss in childhood cancer survivors who are being treated with the drug cisplatin.

14 May 2021

Study paves way for effective monitoring of chemotherapeutic drug level in cancer patients

Cancer is the world's second deadliest disease which contributes towards the fatality of over 10 million people per year.

3 Apr 2021

Phase 3 DREAM3R trial opens for malignant pleural mesothelioma

The DREAM3R phase three clinical trial is now enrolling patients with newly diagnosed unresectable malignant pleural mesothelioma (MPM) throughout the US, Australia, and New Zealand.

17 Mar 2021

Researchers create high throughput arrays of miniaturized 3D tumor models

By engineering common filter papers, similar to coffee filters, a team of NYU Abu Dhabi researchers have created high throughput arrays of miniaturized 3D tumor models to replicate key aspects of tumor physiology, which are absent in traditional drug testing platforms.

22 Feb 2021

New rodent model helps identify pregnant women whose prior kidney injury also affects babies

Young pregnant women, who appear to have fully recovered from an acute injury that reduced their kidney function, have higher rates of significant problems like preeclampsia and low birthweight babies, problems which indicate their kidneys have not actually fully recovered.

22 Feb 2021

Study characterizes cisplatin-induced hearing loss in pediatric cancer patients

Cisplatin is one of the most effective chemotherapy agents, used in just under half of pediatric cancer cases.

13 Feb 2021

Phase III study of (m)RNA expression did not confer significant advantage for stage II-III lung cancer

A phase III study examining whether messenger (m)RNA expression correlated with sensitivity or resistance to chemotherapy did not confer a statistically significant advantage in overall survival for patients with resected stage II-III non-small cell lung cancer (NSCLC), according to research presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.

31 Jan 2021

Nivolumab monotherapy is effective treatment option for relapsed malignant mesothelioma

Nivolumab monotherapy is an effective treatment option for relapsed malignant mesothelioma (MM), according to research presented today at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.

31 Jan 2021

Reduced-dose radiotherapy with cisplatin produces good outcomes for HPV-associated oropharyngeal cancer

A combination of reduced-dose radiotherapy using intensity-modulated radiotherapy (IMRT) combined with concurrent cisplatin met the threshold for disease control and quality of life compared to the standard of care for good-risk patients with HPV-associated oropharyngeal squamous cell carcinoma on the NRG Oncology clinical trial NRG-HN002.

29 Jan 2021

Allarity Therapeutics announces plans to test antiviral activity of stenoparib drug

Allarity Therapeutics of Hørsholm, Denmark, today announced plans to further test the antiviral activity of stenoparib, its PARP inhibitor, against SARS-CoV-2 lineage B.1.1.7, also known as Coronavirus Variant B117 (the "British variant"), at the COVID-19 Testing Service Center (CTSC) of Northern Arizona University's Pathogen and Microbiome Institute (PMI), a leading U.S. infectious disease testing center.

27 Jan 2021

Researchers discover a new approach to inhibit intrahepatic cholangiocarcinoma

Reprogramming the rich connective tissue microenvironment of a liver cancer known as intrahepatic cholangiocarcinoma (ICC) inhibits its progression and resistance to standard chemotherapy in animal models, researchers from Massachusetts General Hospital have found.

12 Jan 2021

Repurposed drug can treat hearing loss in humans

According to the World Health Organization, around 466 million people worldwide have disabling hearing loss, a number the organization projects will double by 2050 to affect 1 in 10 people.

7 Jan 2021

Machine learning increases the accuracy of anti-cancer drug response predictions

With the advent of pharmacogenomics, machine learning research is well underway to predict the patients' drug response that varies by individual from the algorithms derived from previously collected data on drug responses.

2 Nov 2020